Cala Health Inc (Cala Health) is a bioelectronic company that strives to develop new class of electrical medicines. The company’s neuroperipheral therapy treats chronic disease by activating peripheral nerves with body-worn electronics. Its Cala ONE is a non-invasive, targeted nerve stimulator for the treatment of essential tremor. Cala Health aims to provide individualized, prescription neuromodulation therapies in combination with neuroscience and electronics. The company is funded by Lightstone Ventures, Lux Capital, dRx Capital, GV and Action Potential Venture Capital, among others. Cala Health is headquartered in San Mateo, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Cala Health Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Cala Health Inc Company Overview
Cala Health Inc Company Snapshot
Cala Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Cala Health Inc – Pipeline Analysis Overview
Cala Health Inc - Key Facts
Cala Health Inc - Major Products and Services
Cala Health Inc Pipeline Products by Development Stage
Cala Health Inc Ongoing Clinical Trials by Trial Status
Jan 09, 2024: Cala Announces Data from Multiple Clinical Studies Demonstrating Effective Outcomes of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients
Oct 25, 2023: Cala kIQ System to Treat Hand Tremor Named to Time’s List of the Best Inventions of 2023
Jun 14, 2023: Cala Launches The Cala kIQ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease
Apr 19, 2023: Cala introduces next generation system and accelerates leadership in bioelectronic medicine
Dec 02, 2022: Cala Health receives additional 510(k) clearance for Cala kIQ
Sep 27, 2022: Real world evidence of Cala TAPS therapy further supports long-term safety and efficacy of its treatment for essential tremor
May 18, 2022: Cala Partners with SK Biopharmaceuticals to Fuel Innovation in Neurology
Apr 04, 2022: New research presented at AAN demonstrates burden associated with essential tremor and the unmet patient need
Mar 01, 2022: Cala Health is building momentum by expanding affordable access for patients with essential tremor
Oct 12, 2021: Cala Health receives additional 510(k) clearance for Cala Trio
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: Cala Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Table 2: Cala Health Inc Pipeline Products by Equipment Type
Table 3: Cala Health Inc Pipeline Products by Indication
Table 4: Cala Health Inc, Key Facts
Table 5: Cala Health Inc, Major Products and Services
Table 6: Cala Health Inc Number of Pipeline Products by Development Stage
Table 7: Cala Health Inc Pipeline Products Summary by Development Stage
Table 8: Cala Health Inc Ongoing Clinical Trials by Trial Status
Table 9: Cala Health Inc Ongoing Clinical Trials Summary
Table 10: Cala Trio - Action Tremor - Product Status
Table 14: RAVANS Device - Investigating the Safety and Efficacy of Respiratory-Gated Auricular Vagal Afferent Nerve Stimulation (RAVANS) in Ulcerative Colitis (UC) in Pediatric and Young Adult Populations
Table 15: Wearable Neuromodulation Device - Product Status